Boston Scientific has proven itself to be a fierce competitor among three major cardiac device makers, with a track record of meaningful innovation and impressive operational chops. Even a prolonged ...

The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

Thanks to healthcare reform, the hurdles to securing reimbursement and technology add-on payments have risen. Boston will need to invest more in clinical studies to demonstrate superiority of outcomes ...

For over a decade, the McGill University Health Centre (MUHC) has been at the forefront of aortic valve innovation, advancing ...

For a balloon-expandable transcatheter aortic valve replacement (TAVR or TAVI ... a higher skirt, wider stent frame, and shorter frame height. Notably, the maker of the Sapien 3, Edwards ...

Bioprosthetic valve dysfunction and reoperations/reinterventions are common after aortic valve replacement (AVR) with bioprosthetic valves, leading to cycles of left ...

“That’s the key.” By his side, Cardiologist Dr. Stan Watkins explained how it all happens. “It’s a stent, basically, that’s crimped onto a balloon, put onto over a wire, in through the leg, up to the ...

Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of measuring the ...

This case highlights a scenario where there was difficulty navigating a pigtail catheter across the valve, followed by a coronary artery obstruction subsequent to stent deployment. The issue with the ...